H.C. Wainwright Maintains Oric Pharmaceuticals(ORIC.US) With Buy Rating, Maintains Target Price $21
Wells Fargo Initiates Oric Pharmaceuticals(ORIC.US) With Buy Rating, Announces Target Price $20
Oric Pharmaceuticals Initiated at Buy by Jones Trading
ORIC Pharmaceuticals Analyst Ratings
JonesTrading Initiates Oric Pharmaceuticals(ORIC.US) With Buy Rating, Announces Target Price $17
HC Wainwright & Co. Reiterates Buy on ORIC Pharmaceuticals, Maintains $21 Price Target
H.C. Wainwright Maintains Oric Pharmaceuticals(ORIC.US) With Buy Rating, Maintains Target Price $21
Buy Rating Affirmed for Oric Pharmaceuticals Amid Promising Collaborations and Strategic Clinical Advances
Wedbush Maintains Oric Pharmaceuticals(ORIC.US) With Buy Rating, Maintains Target Price $20
Oric Pharmaceuticals (ORIC) Gets a Buy From Wedbush
ORIC Pharmaceuticals Analyst Ratings
Stifel Maintains Oric Pharmaceuticals(ORIC.US) With Buy Rating, Maintains Target Price $20
Stifel Initiates Oric Pharmaceuticals(ORIC.US) With Buy Rating, Announces Target Price $20
H.C. Wainwright Maintains Oric Pharmaceuticals(ORIC.US) With Buy Rating, Maintains Target Price $21
HC Wainwright & Co. Reiterates Buy on ORIC Pharmaceuticals, Maintains $21 Price Target
Oric Pharmaceuticals Price Target Maintained With a $20.00/Share by Wedbush
Wedbush Maintains Oric Pharmaceuticals(ORIC.US) With Buy Rating, Maintains Target Price $20
Oppenheimer Maintains Oric Pharmaceuticals(ORIC.US) With Buy Rating, Cuts Target Price to $15
Wedbush Initiates a Buy Rating on Oric Pharmaceuticals (ORIC)
Analysts Conflicted on These Healthcare Names: Oric Pharmaceuticals (ORIC), Aerovate Therapeutics (AVTE) and McKesson (MCK)